Farallon Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Farallon Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-451,700	Closed	-$46.1M	–	185
2023 Q2	$46.1M	Buy	451,700 +126,700	+39%	+$12M	0.23%	68
2023 Q1	$29.5M	Sell	325,000 -7,000	-2%	-$411K	0.16%	71
2022 Q4	$12.6M	Buy	+332,000	New	+$11.4M	0.07%	95
2020 Q1	–	Sell	-75,000	Closed	-$15.3M	–	118
2019 Q4	$15.3M	Sell	75,000 -107,060	-59%	-$19.5M	0.1%	92
2019 Q3	$14.6M	Sell	182,060 -617,940	-77%	-$52.4M	0.11%	79
2019 Q2	$75.5M	Buy	800,000 +50,000	+7%	+$4.32M	0.49%	49
2019 Q1	$64.1M	Buy	750,000 +50,000	+7%	+$4.15M	0.48%	48
2018 Q4	$39.3M	Buy	700,000 +26,500	+4%	+$1.62M	0.29%	52
2018 Q3	$55.1M	Buy	+673,500	New	+$47.5M	0.33%	47

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Farallon Capital Management's RETA Position: Q3 2023 in Review

Farallon Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 451,700 shares — an estimated $46.1M sold.

Farallon Capital Management first reported a position in RETA in Q3 2018 and held it in 9 quarters. The position peaked at $75.5M in Q2 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Farallon Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Farallon Capital Management sold 451,700 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $46.1M.
Farallon Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 9 quarters.
Farallon Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $75.5M in Q2 2019.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Farallon Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.